Skip to main content
Figure 2 | Cardiovascular Diabetology

Figure 2

From: Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease

Figure 2

Association between serum levels of incretins, glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP), and metabolic syndrome components in patients with atherosclerosis-prone conditions. Circulating levels of GLP-1 (A) and GIP (B) were measured in high-risk patients with atherosclerosis. Metabolic score is the number of metabolic syndrome components; abdominal obesity, hypertension, dyslipidemia (high triglyceride and/or low high density lipoprotein cholesterol), and hyperglicemia (impaired glucose tolerance or diabetes). Progressive increase in GLP-1 level as a function of the number of MetS components (P < 0.001).

Back to article page